Medulloblastoma: Pediatric vs. Adult Incidence and Risk Factors

Medulloblastoma is the most common malignant pediatric brain tumor (~20% of childhood CNS tumors).

  • Peak incidence: Ages 5–9 years.
  • Sex bias: Male > female (1.5:1).
  • Adults: Rare (<1% of adult brain tumors).

Molecular Subgroups (Prognostic & Therapeutic)

  1. WNT-activated (best prognosis).
  2. SHH-activated (intermediate; infant vs. adult differ).
  3. Group 3 (poor prognosis; often metastatic).
  4. Group 4 (most common; intermediate).

Treatment

Maximal safe resection → risk-adapted craniospinal irradiation + chemotherapy (cisplatin, vincristine, cyclophosphamide). Survival: ~70–80% overall at 5 years (varies by subgroup/age).

Late effects: neurocognitive, endocrine, hearing, second malignancies – long-term follow-up essential.

Pediatrics - Related Articles